Announcement PDF RNS Number : 2525O Genedrive PLC 28 May 2020 genedrive plc ("genedrive" or the "Company") Application for Block Listing genedrive plc (LSE: GDR), the near patient molecular diagnostics company, today announces that an application has been made to the London Stock Exchange for a block listing of 300,000 new ordinary shares of 1.5p each ('Ordinary Shares') in genedrive in respect of Ordinary Shares that are to be allotted under the genedrive 2007 Share Option Scheme. It is expected that the 300,000 Ordinary Shares will be admitted to trading on 4 June 2020. The shares will rank pari passu with the existing Ordinary Shares of the Company. genedrive plc David Budd: CEO / Matthew Fowler: CFO +44 (0)161 989 0245 Peel Hunt LLP (Nominated Adviser and Joint Broker) James Steel / Oliver Jackson +44 (0)20 7418 8900 finnCap (Joint Broker) Geoff Nash / Kate Bannatyne / Alice Lane +44 (0)20 7220 0500 Walbrook PR Ltd (Media & Investor Relations) Paul McManus / Anna Dunphy +44 (0)20 7933 8780 or genedrive@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 741 001 About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently announced the development of a high throughput SARS-CoV-2 assay and a Genedrive® Point of Care version of the assay, both based on Genedrive® PCR chemistry. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END ALSSEWFEAESSEFI